News World Moderna's COVID-19 vaccine shows promise in early study, shares soar

Moderna’s COVID-19 vaccine shows promise in early study, shares soar

Moderna Inc said on Monday its experimental COVID-19 vaccine showed promise in a small early-stage trial, with the vaccine producing virus-neutralizing antibodies similar to that found in recovered patients, sending shares soaring 25%.

The company’s vaccine is at the forefront of the efforts in developing a treatment for the fast-spreading virus and last week, won the U.S. health agency’s “fast track” label to speed up the regulatory review. Moderna expects to start a larger late-stage trial in July.

There are currently no approved treatment or vaccine for COVID-19, caused by the new coronavirus, and experts predict a safe and effective vaccine could take 12-18 months to develop.

Eight patients who were administered Moderna’s vaccine were found to have antibody levels similar to those in blood samples of people who have recovered from COVID-19, according to early results from the study conducted by the National Institutes of Health.

All 45 participants in the study were given three different doses of the vaccine and Moderna said it saw dose-dependent increase in immunogenicity, the ability to provoke an immune response in the body.

“We are investing to scale up manufacturing so we can maximize the number of doses we can produce to help protect as many people as we can from SARS-CoV-2,” Moderna Chief Executive Officer Stéphane Bancel said.

The company has signed deals with Swiss contract drugmaker Lonza Group AG and the U.S. government to produce massive quantities of its vaccine.

The vaccine, mRNA-1273, was also found to be generally safe and well tolerated in the early-stage study, the drug developer said.

One person in the trial experienced redness around the injection site, which was characterized as a “grade 3” side effect. No serious side effects had been reported, the company said.

Moderna shares have risen 240% in the year through Friday’s close.

(Reuters)

Top Stories

Three covid deaths in Cyprus, new cases drop further to 157 but fewer tests

  Cyprus recorded three covid deaths over the past 24 hours, raising the number to 170,  113 men and 57 women, with an average age...

Thousands protest in Amsterdam against Dutch coronavirus lockdown

  Several thousand today people held an unauthorised protest in Amsterdam against a national lockdown to slow the spread of the coronavirus pandemic, before being...

Search and rescue crews looking for woman off Larnaca

  The Search and Rescue Coordination Centre in Larnaca received a call around four in the afternoon about a 70 year old woman missing off...

Rapid Test locations on Monday Jan 18

Here are the rapid test locations for Monday January 18 Limassol Apostolos Loukas church, Ayios Athanasios (Ayios Athanasios refugee settlement) 8.30-4.30 Ayios Stylianos church, Linopetra 8.30-4.30 Mesa Yeitonia Cultural Centre...

German FM says COVID curbs should be eased for vaccinated people

  People who have been vaccinated against COVID-19 should be allowed to go to restaurants and cinemas earlier than others, a German minister said, contradicting...

Taste

Squash soup

Ingredients: 1 kg pumpkin, cut into small cubes, approximately 5 cups 2 medium (400g) sweet potatoes, cut into cubes, approximately 2 ½ cups 1 chopped leek, only...

Mezedes

No visit to Cyprus is complete without enjoying the traditional meal of many small dishes known as ‘meze’. This large feast, which has been a...

Prawns with fried cheese, barley shaped pasta

Put the barley shaped pasta into a small pan with salted water, bring to a boil and when tender, drain. Peal the prawns leaving...

Salmon and shrimp sheftalies

Mix all ingredients for tabbouli in a bowl and keep to one side so flavours can combine. Prepare the sheftalies: wash and soak the casing...